Calculating the approximate worth of Tandem Diabetes Care ($NASDAQ:TNDM), Inc. can be a daunting task, but it is essential for investors who wish to make informed decisions about their investments. Tandem Diabetes Care, Inc. is a publically traded company that focuses on providing comprehensive diabetes care and solutions to individuals and healthcare providers worldwide. The company is dedicated to improving the lives of people with diabetes by developing innovative products and technologies that simplify the management of their disease. Tandem Diabetes Care provides a range of products and services to assist people with diabetes, such as insulin pumps, glucose monitors, app-based diabetes management systems, and patient education resources.
In addition, the company’s research and development efforts are aimed at creating new technologies that will further reduce the burden of diabetes management. The company also plays an important role in the global fight against diabetes by providing financial support for organizations that are dedicated to finding a cure for the disease. By taking into account the various aspects of Tandem Diabetes Care’s operations, investors can calculate the approximate worth of the company and determine if it is an appropriate investment for them. This includes evaluating the current stock price, analyzing the company’s financials, and understanding the risks associated with investing in the company. With a thorough understanding of Tandem Diabetes Care, investors can make informed decisions and have confidence in the potential returns on their investments.
Tandem Diabetes Care, Inc. saw a positive movement in the stock market on Monday, with its stock opening at $17.8 and closing at $18.4. This marked a 3.5% increase from its prior closing price of $17.8. This sudden surge in the company’s share price illustrates the strong potential of the diabetes care provider, thus demonstrating its true worth in the competitive market. As such, it is evident that Tandem Diabetes Care, Inc. is well-positioned to benefit investors in the long-term. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for TNDM. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TNDM. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TNDM. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for TNDM are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – TNDM Intrinsic Value Calculation
At GoodWhale, we believe in quantifying the fundamentals of a stock to arrive at an unbiased valuation of its stock. That’s why we analyze the fundamentals of TANDEM DIABETES CARE and arrive at a value of around $79.6 using our proprietary Valuation Line. This means that the current market price of $18.4 is 76.9% lower than the intrinsic value we calculated. In other words, TANDEM DIABETES CARE is currently undervalued, making it an attractive investment opportunity. More…
Star Chart Analysis
The market for diabetes care products is highly competitive, with major players such as Tandem Diabetes Care Inc, NuVasive Inc, Avanos Medical Inc, and Penumbra Inc vying for market share. While each company has its own strengths and weaknesses, the competition between them is fierce, and it is often the case that one company’s success comes at the expense of its rivals.
NuVasive Inc is a medical device company that develops minimally-invasive surgical products and procedures for spine surgery. The company has a market cap of 2.17B as of 2022 and a Return on Equity of -1.33%. NuVasive’s products and procedures are designed to improve patient outcomes and minimize surgical invasiveness. The company’s products are used in a variety of spine surgeries, including lumbar, thoracic, and cervical procedures.
– Avanos Medical Inc ($NYSE:AVNS)
Avanos Medical Inc is a medical technology company that focuses on developing and commercializing minimally invasive medical devices. The company has a market cap of 957.63M as of 2022 and a Return on Equity of 2.85%. Avanos’ products are used in a variety of procedures, including pain management, gastrointestinal, urological, ENT, and vascular.
As of 2022, Penumbra Inc has a market cap of 6.49B and a Return on Equity of -2.31%. The company is a medical device company that develops, manufactures and markets products for the treatment of neurovascular diseases.
Investors interested in Tandem Diabetes Care, Inc. (TNDM) should consider a variety of factors when estimating the stock’s fair value. Fundamental analysis requires looking at the financial health of the company, such as its revenue and profits, and evaluating potential risks. Analysts should also assess the performance of the stock against industry peers and the overall market. Technical analysis involves analyzing the price movements and trading volumes of the stock over time.
Investors can also assess the company’s future prospects by considering various macroeconomic and industry trends, as well as management’s strategy and execution track record. Recent news related to the company also provides insight into how the stock may be valued in the future. By analyzing all these factors, investors can make an informed decision on whether TNDM is a good investment.